| Date Filed | Type | Description |
| 08/16/2023 |
8-K
| Investor presentation |
| 08/10/2023 |
SC 13G/A
| FMR LLC reports a 6.9% stake in DAY ONE BIOPHARMACEUTICALS INC |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Investor presentation, Quarterly results |
| 06/12/2023 |
SC 13D/A
| AI Day1 LLC reports a 13.2% stake in Day One Biopharmaceuticals, Inc. |
| 06/12/2023 |
8-K
| Investor presentation |
| 06/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"Day One Announces Pricing of Public Offering of Common Stock BRISBANE, Calif., June 6, 2023 - Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All shares of common stock are being offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $150.0 million. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,730,769 shares of..." |
|
| 06/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/06/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/06/2023 |
8-K
| Other Events Interactive Data |
| 06/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/01/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
8-K
| Investor presentation, Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Investor presentation, Quarterly results |
| 02/23/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.6% stake in Day One Biopharmaceuticals, Inc. |
| 02/13/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G/A
| TAKEDA PHARMACEUTICAL CO LTD reports a 0% stake in Exit Filing)* DAY ONE BIOPHARMACEUTICALS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Investor presentation, Quarterly results |
| 10/19/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/22/2022 |
SC 13D/A
| Canaan XI L.P. reports a 9.5% stake in DAY ONE BIOPHARMACEUTICALS, INC. |
| 09/19/2022 |
SC 13D/A
| Canaan XI L.P. reports a 12.7% stake in DAY ONE BIOPHARMACEUTICALS, INC. |
| 09/12/2022 |
SC 13G
| FMR LLC reports a 11.3% stake in DAY ONE BIOPHARMACEUTICALS INC |
|